EXCLUSIVE ONLINE CONTENT
Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine
LogicBio Therapeutics, Inc. recently announced it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio. The proposed acquisition…
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics, Inc. recently announced the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1)…..
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
Cidara Therapeutics, Inc. recently announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus…..
SiSaf Announces Positive Preclinical Data for its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
SiSaf Ltd, an RNA delivery and therapeutics company, recently announce positive data confirming safety and efficacy of its Bio-Courier next-generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an….
Aptose Biosciences Inc. recently announced the G3 formulation of luxeptinib, designed for rapid and efficient absorption, demonstrates approximately an 18-fold improvement in oral bioavailability….
MARKET NEWS & TRENDS
Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..
WHITEPAPER – Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration
Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics offers several advantages. Enteris BioPharma’s…
Download this white paper to learn more about the applications of silica and metal-based nanoparticles in drug delivery and photothermal therapy…..
Particle Works’ leading microfluidic technology offers a unique automated nanoparticle generation platform for the production of homogeneous, controllable, and reproducible LNPs….
Antibody production is a multi-step complex process and generating reproducible antibodies is highly critical for immunoassays-based research, immunodiagnostics, and immunotherapy. Antibodies’ reproducibility is driven by…
ProPerma™ uniquely improves both permeability and bioavailability of BCS III and BCS IV compounds by deploying an innovative and bespoke combination of GRAS and novel enhancing excipients…